Cormica Recognised as 2025 Leading Pharmaceutical and Medical Device Testing Specialists

Cormica is proud to announce it has been awarded the title of 2025's leading pharmaceutical and medical device testing specialists, by Global Health & Pharma Magazine (GHP)

by Marketing Department | Friday 27 February 2026

Cormica_Recognised_2025_Leading_Pharmaceutical.jpg
The award recognises Cormica’s consistent delivery of high-quality, compliant testing across its global laboratory network, supporting regulated product development and release across international markets.

Cormica was commended for consistent delivery of high-quality, compliant testing across our network of GMP, GLP, and ISO 17025 accredited laboratories in the UK, US, and EU. It reflects the group's strong quality systems, deep technical expertise, and collaborative approach to supporting clients across the full product lifecycle, from early development through to regulatory submission, product release, and post-market activities.

Cormica supports manufacturers operating in highly regulated and rapidly evolving markets, helping them navigate changing regulatory requirements and bring safe, effective products to market with confidence. Cormica’s integrated service offering spans microbiology, analytical chemistry, physical and packaging testing, biocompatibility, and regulatory support, enabling manufacturers to manage complex testing programmes through a single, coordinated partner. This joined-up approach allows clients to reduce risk, improve efficiency, and maintain confidence in product quality throughout development and commercialisation.

Central to this recognition is Cormica’s values-led culture, with a clear focus on doing what is right, taking ownership, working collaboratively across sites, and continually improving capabilities to meet evolving regulatory expectations.
By supporting manufacturers in developing, registering, and releasing medical device and pharmaceutical products, Cormica plays a vital role in enabling patient access to safe and effective therapies worldwide. The award reflects not only technical capability, but the everyday standards and decisions that underpin trust in regulated testing.

Mark Hammond, Chief Executive Officer, Cormica, said: “We are proud that Cormica has been recognised as 2025’s Leading Pharmaceutical & Medical Device Testing Specialists. This award reflects the consistency, integrity, and professionalism our teams demonstrate every day across the group. Our clients rely on us for accurate, reliable, and compliant data, and this recognition reinforces the trust they place in us as their testing partner.”

Improving Patient Lives Through Trusted Testing
For our clients, the award provides independent reassurance that Cormica delivers testing services to a consistently high standard across all sites. It reinforces Cormica’s role as a dependable partner for manufacturers navigating regulatory complexity, supporting faster decision-making, smoother submissions, and confident product release across global markets.

By supporting manufacturers in developing, registering, and releasing medical device and pharmaceutical products, Cormica plays a vital role in enabling patient access to safe and effective therapies worldwide. The award reflects not only technical capability, but the everyday standards and decisions that underpin trust in regulated testing.

About Cormica
Cormica is a global network of accredited laboratories in the UK, EU and USA, providing microbiology, analytical chemistry, physical and functional testing, and consultancy services from early R&D through to post-market surveillance. Cormica supports pharmaceutical and medical device manufacturers with compliant testing that accelerates regulatory approval and commercial release.

CONTACT

Marketing Department
Cormica Ltd
mail@wickhamlabs.co.uk
www.cormica.com
+44 1329 226600

Friday 27 February 2026 / file under Biotechnology | Medical | Pharmaceuticals